You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDiethylstilbestrol
Accession NumberDB00255  (APRD00920, EXPT01164)
TypeSmall Molecule
GroupsApproved
DescriptionA synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed)
Structure
Thumb
Synonyms
(E)-3,4-bis(4-hydroxyphenyl)-3-hexene
(e)-4,4'-(1,2-Diethyl-1,2-ethenediyl)bisphenol
4,4'-Dihydroxy-alpha,beta-diethylstilbene
4,4'-dihydroxy-α,β-diethylstilbene
alpha,Alpha'-diethyl-(e)-4,4'-stilbenediol
DES
Diethylstilbestrol
Diethylstilbestrolum
Dietilestilbestrol
Distilbene
Stilboestrol
trans-4,4'-(1,2-diethyl-1,2-ethenediyl)bisphenol
trans-Diethylstilbesterol
trans-Diethylstilbestrol
trans-Diethylstilboesterol
α,α'-diethyl-(E)-4,4'-stilbenediol
External Identifiers
  • RCRA waste number U089
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Honvol Ampoules 250mgliquid250 mgintravenousCarter Horner Corp.1956-12-312000-11-17Canada
Honvol Tablets 100mgtablet100 mgoralCarter Horner Corp.1958-12-312001-05-22Canada
Stilbestrol 0.5mg Tablettablet.5 mgoralGlaxo Canada Inc1993-12-311998-07-30Canada
Stilbestrol 1.0mg Tablettablet1 mgoralGlaxo Canada Inc1991-12-311996-09-10Canada
Stilbestrol Tab 1mgtablet1 mgEverest Pharmaceuticals Ltd.1980-12-311999-07-14Canada
Stilbestrol Tablets 0.1 mgtablet0.105 mgoralWellspring Pharmaceutical Canada Corp1996-07-302009-02-23Canada
Stilbestrol Tablets 0.5 mgtablet0.51 mgoralWellspring Pharmaceutical Canada Corp1997-04-022009-02-23Canada
Stilbestrol Tablets 1.0 mgtablet1.0 mgoralWellspring Pharmaceutical Canada Corp1996-07-302009-02-23Canada
Stilboestrol Tab 0.1mgtablet.1 mgoralAllen & Hanburys A Glaxo Canada Ltd. Co.1951-12-311996-09-10Canada
Stilboestrol Tab 0.5mgtablet.5 mgoralAllen & Hanburys A Glaxo Canada Ltd. Co.1951-12-311996-09-20Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DistilbeneGerda
StilbestrolNysco
StilbetinBristol Myers-Squibb
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Diethylstilbestrol diphosphate
ThumbNot applicableDBSALT001389
Diethylstilbestrol diphosphate sodium
ThumbNot applicableDBSALT001169
Categories
UNII731DCA35BT
CAS number56-53-1
WeightAverage: 268.3502
Monoisotopic: 268.146329884
Chemical FormulaC18H20O2
InChI KeyInChIKey=RGLYKWWBQGJZGM-ISLYRVAYSA-N
InChI
InChI=1S/C18H20O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h5-12,19-20H,3-4H2,1-2H3/b18-17+
IUPAC Name
4-[4-(4-hydroxyphenyl)hex-3-en-3-yl]phenol
SMILES
CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassStilbenes
Sub ClassNot Available
Direct ParentStilbenes
Alternative Parents
Substituents
  • Stilbene
  • Phenylpropene
  • Phenylpropane
  • Phenol
  • Benzenoid
  • Monocyclic benzene moiety
  • Hydrocarbon derivative
  • Organooxygen compound
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed in the treatment of prostate cancer. Previously used in the prevention of miscarriage or premature delivery in pregnant women prone to miscarriage or premature delivery.
PharmacodynamicsDiethylstilbestrol is a synthetic estrogen that was developed to supplement a woman's natural estrogen production. In 1971, the Food and Drug Administration (FDA) issued a Drug Bulletin advising physicians to stop prescribing DES to pregnant women because it was linked to a rare vaginal cancer in female offspring.
Mechanism of actionEstrogens diffuse into their target cells and interact with a protein receptor, the estrogen receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. The effect of Estrogen binding their receptors causes downstream increases the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH).
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySymptoms of overdose include nausea and vomiting, and withdrawal bleeding may occur in females.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9973
Blood Brain Barrier-0.5559
Caco-2 permeable+0.8264
P-glycoprotein substrateSubstrate0.5737
P-glycoprotein inhibitor INon-inhibitor0.6542
P-glycoprotein inhibitor IINon-inhibitor0.8478
Renal organic cation transporterNon-inhibitor0.8465
CYP450 2C9 substrateNon-substrate0.8149
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5107
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorInhibitor0.9064
CYP450 2D6 inhibitorNon-inhibitor0.7017
CYP450 2C19 inhibitorInhibitor0.9198
CYP450 3A4 inhibitorInhibitor0.8361
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9488
Ames testNon AMES toxic0.9579
CarcinogenicityNon-carcinogens0.6772
BiodegradationNot ready biodegradable0.9111
Rat acute toxicity1.9462 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6894
hERG inhibition (predictor II)Non-inhibitor0.6408
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Bristol myers squibb
  • Eli lilly and co
  • Tablicaps inc
  • Bayer pharmaceuticals corp
Packagers
Dosage forms
FormRouteStrength
Liquidintravenous250 mg
Tabletoral100 mg
Tabletoral1 mg
Tablet1 mg
Tabletoral0.105 mg
Tabletoral0.51 mg
Tabletoral1.0 mg
Tabletoral.1 mg
Tabletoral.5 mg
Prices
Unit descriptionCostUnit
Diethylstilbestrol powder13.77USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point172Adler, E.,Gie, G.J. and von Euler, H.; US. Patent 2,421,401; June 3, 1947; assigned to Hoffmann-La Roche, Inc.
water solubility12 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP5.07HANSCH,C ET AL. (1995)
logS-4.35ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0109 mg/mLALOGPS
logP4.62ALOGPS
logP5.19ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)9.13ChemAxon
pKa (Strongest Basic)-6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area40.46 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity83.24 m3·mol-1ChemAxon
Polarizability30.69 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (9.87 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Adler, E.,Gie, G.J. and von Euler, H.; US. Patent 2,421,401; June 3, 1947; assigned to Hoffmann-La Roche, Inc.

General References
  1. Authors unspecified: Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. N Engl J Med. 1984 Nov 15;311(20):1281-6. [PubMed:6436700 ]
  2. DIECKMANN WJ, DAVIS ME, RYNKIEWICZ LM, POTTINGER RE: Does the administration of diethylstilbestrol during pregnancy have therapeutic value? Am J Obstet Gynecol. 1953 Nov;66(5):1062-81. [PubMed:13104505 ]
  3. Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols LK, Nichols WC, Creagan ET, Hahn RG, Rubin J, Frytak S: Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med. 1981 Jan 1;304(1):16-21. [PubMed:7001242 ]
  4. Kuchera LK: Postcoital contraception with diethylstilbestrol. JAMA. 1971 Oct 25;218(4):562-3. [PubMed:5171004 ]
  5. Herbst AL, Ulfelder H, Poskanzer DC: Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med. 1971 Apr 15;284(15):878-81. [PubMed:5549830 ]
External Links
ATC CodesL02AA01G03CC05G03CB02
AHFS Codes
  • 68:16.04
PDB Entries
FDA labelNot Available
MSDSDownload (73.1 KB)
Interactions
Drug Interactions
Drug
4-AndrostenedioneThe serum concentration of 4-Androstenedione can be increased when it is combined with Diethylstilbestrol.
AbciximabDiethylstilbestrol may decrease the anticoagulant activities of Abciximab.
AcenocoumarolDiethylstilbestrol may decrease the anticoagulant activities of Acenocoumarol.
AcetaminophenThe serum concentration of Diethylstilbestrol can be increased when it is combined with Acetaminophen.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Diethylstilbestrol.
AfatinibThe serum concentration of Diethylstilbestrol can be increased when it is combined with Afatinib.
AlbendazoleThe serum concentration of Diethylstilbestrol can be increased when it is combined with Albendazole.
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Diethylstilbestrol.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Diethylstilbestrol.
AldosteroneThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Diethylstilbestrol can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Diethylstilbestrol can be increased when it is combined with Alfentanil.
AmantadineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Amantadine.
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Diethylstilbestrol.
Aminohippuric acidThe serum concentration of Diethylstilbestrol can be increased when it is combined with Aminohippuric acid.
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Diethylstilbestrol.
AmiodaroneThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Amitriptyline.
AmlodipineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Amlodipine.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Diethylstilbestrol.
AmprenavirThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Amsacrine.
AnastrozoleThe therapeutic efficacy of Anastrozole can be decreased when used in combination with Diethylstilbestrol.
AncrodDiethylstilbestrol may decrease the anticoagulant activities of Ancrod.
Anthrax immune globulin humanDiethylstilbestrol may increase the thrombogenic activities of Anthrax immune globulin human.
Antithrombin III humanDiethylstilbestrol may decrease the anticoagulant activities of Antithrombin III human.
ApixabanDiethylstilbestrol may decrease the anticoagulant activities of Apixaban.
ArdeparinDiethylstilbestrol may decrease the anticoagulant activities of Ardeparin.
ArgatrobanDiethylstilbestrol may decrease the anticoagulant activities of Argatroban.
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Diethylstilbestrol resulting in a loss in efficacy.
AstemizoleThe serum concentration of Diethylstilbestrol can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Diethylstilbestrol can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Diethylstilbestrol can be increased when it is combined with Atenolol.
AtorvastatinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Atorvastatin.
AzelastineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Azelastine.
AzithromycinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Azithromycin.
BecaplerminDiethylstilbestrol may decrease the anticoagulant activities of Becaplermin.
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Diethylstilbestrol.
BenzocaineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Benzocaine.
BepridilThe serum concentration of Diethylstilbestrol can be increased when it is combined with Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Diethylstilbestrol.
BevacizumabBevacizumab may increase the cardiotoxic activities of Diethylstilbestrol.
BiperidenThe serum concentration of Diethylstilbestrol can be increased when it is combined with Biperiden.
BivalirudinDiethylstilbestrol may decrease the anticoagulant activities of Bivalirudin.
BosutinibThe serum concentration of Diethylstilbestrol can be increased when it is combined with Bosutinib.
BromocriptineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Bromocriptine.
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Diethylstilbestrol.
BuprenorphineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Buprenorphine.
BuspironeThe serum concentration of Diethylstilbestrol can be increased when it is combined with Buspirone.
C1 Esterase Inhibitor (Human)Diethylstilbestrol may increase the thrombogenic activities of C1 Esterase Inhibitor (Human).
C1 Esterase Inhibitor (Recombinant)Diethylstilbestrol may increase the thrombogenic activities of C1 Esterase Inhibitor (Recombinant).
CabazitaxelThe serum concentration of Diethylstilbestrol can be increased when it is combined with Cabazitaxel.
CaffeineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Caffeine.
CanagliflozinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Diethylstilbestrol can be increased when it is combined with Candesartan.
CaptoprilThe serum concentration of Diethylstilbestrol can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Carbamazepine.
CarvedilolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Diethylstilbestrol can be increased when it is combined with Caspofungin.
CertoparinDiethylstilbestrol may decrease the anticoagulant activities of Certoparin.
Chenodeoxycholic acidThe therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Diethylstilbestrol.
ChloroquineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Chloroquine.
ChlorpromazineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Diethylstilbestrol can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Diethylstilbestrol can be increased when it is combined with Chlorprothixene.
CholesterolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Cholic Acid.
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Diethylstilbestrol.
CilazaprilThe serum concentration of Diethylstilbestrol can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Cimetidine.
CiprofloxacinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Ciprofloxacin.
CitalopramThe serum concentration of Diethylstilbestrol can be increased when it is combined with Citalopram.
Citric AcidDiethylstilbestrol may decrease the anticoagulant activities of Citric Acid.
ClarithromycinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Clarithromycin.
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Diethylstilbestrol.
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Diethylstilbestrol.
ClofazimineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Clofazimine.
ClomipramineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Clomipramine.
ClotrimazoleThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Clotrimazole.
CobicistatThe serum concentration of Diethylstilbestrol can be increased when it is combined with Cobicistat.
ColchicineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Colforsin.
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Diethylstilbestrol.
CrizotinibThe serum concentration of Diethylstilbestrol can be increased when it is combined with Crizotinib.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Diethylstilbestrol.
CyclosporineThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Cyclosporine.
Dabigatran etexilateDiethylstilbestrol may decrease the anticoagulant activities of Dabigatran etexilate.
DaclatasvirThe serum concentration of Diethylstilbestrol can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Dactinomycin.
DalteparinDiethylstilbestrol may decrease the anticoagulant activities of Dalteparin.
DanaparoidDiethylstilbestrol may decrease the anticoagulant activities of Danaparoid.
DasatinibThe serum concentration of Diethylstilbestrol can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Daunorubicin.
DehydroepiandrosteroneThe risk or severity of adverse effects can be increased when Dehydroepiandrosterone is combined with Diethylstilbestrol.
DehydroepiandrosteroneThe serum concentration of Dehydroepiandrosterone can be increased when it is combined with Diethylstilbestrol.
dehydroepiandrosterone sulfateThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Diethylstilbestrol.
DesipramineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Desipramine.
DesirudinDiethylstilbestrol may decrease the anticoagulant activities of Desirudin.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Diethylstilbestrol.
DesloratadineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Desloratadine.
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Diethylstilbestrol.
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Diethylstilbestrol.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Diethylstilbestrol.
DexamethasoneThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Dexamethasone.
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Diethylstilbestrol.
DextranDiethylstilbestrol may decrease the anticoagulant activities of Dextran.
Dextran 40Diethylstilbestrol may decrease the anticoagulant activities of Dextran 40.
Dextran 70Diethylstilbestrol may decrease the anticoagulant activities of Dextran 70.
Dextran 75Diethylstilbestrol may decrease the anticoagulant activities of Dextran 75.
DextromethorphanThe serum concentration of Diethylstilbestrol can be increased when it is combined with Dextromethorphan.
DiclofenacThe serum concentration of Diethylstilbestrol can be increased when it is combined with Diclofenac.
DicoumarolDiethylstilbestrol may decrease the anticoagulant activities of Dicoumarol.
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Diethylstilbestrol.
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Diethylstilbestrol.
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Diethylstilbestrol.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Diethylstilbestrol.
DigoxinDigoxin may decrease the cardiotoxic activities of Diethylstilbestrol.
DihydroergotamineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Dihydroergotamine.
DiltiazemThe serum concentration of Diethylstilbestrol can be increased when it is combined with Diltiazem.
DipyridamoleThe serum concentration of Diethylstilbestrol can be increased when it is combined with Dipyridamole.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Diethylstilbestrol.
DoxazosinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Doxorubicin.
DronabinolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Dronabinol.
DronedaroneThe serum concentration of Diethylstilbestrol can be increased when it is combined with Dronedarone.
DyphyllineThe serum concentration of Dyphylline can be increased when it is combined with Diethylstilbestrol.
Edetic AcidDiethylstilbestrol may decrease the anticoagulant activities of Edetic Acid.
EdoxabanDiethylstilbestrol may decrease the anticoagulant activities of Edoxaban.
ElbasvirThe serum concentration of Diethylstilbestrol can be increased when it is combined with Elbasvir.
EnalaprilThe serum concentration of Diethylstilbestrol can be increased when it is combined with Enalapril.
EnoxaparinDiethylstilbestrol may decrease the anticoagulant activities of Enoxaparin.
EntacaponeThe metabolism of Diethylstilbestrol can be decreased when combined with Entacapone.
EnzalutamideThe serum concentration of Diethylstilbestrol can be increased when it is combined with Enzalutamide.
EquileninThe serum concentration of Equilenin can be increased when it is combined with Diethylstilbestrol.
EquilinThe serum concentration of Equilin can be increased when it is combined with Diethylstilbestrol.
ErgonovineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Ergotamine.
ErythromycinThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Erythromycin.
EstramustineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Estrone can be increased when it is combined with Diethylstilbestrol.
EstroneThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Estrone.
Ethyl biscoumacetateDiethylstilbestrol may decrease the anticoagulant activities of Ethyl biscoumacetate.
EtoposideThe serum concentration of Diethylstilbestrol can be increased when it is combined with Etoposide.
EtravirineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Etravirine.
ExemestaneThe therapeutic efficacy of Exemestane can be decreased when used in combination with Diethylstilbestrol.
FelodipineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Felodipine.
FentanylThe serum concentration of Diethylstilbestrol can be increased when it is combined with Fentanyl.
FexofenadineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Fidaxomicin.
FluconazoleThe serum concentration of Diethylstilbestrol can be increased when it is combined with Fluconazole.
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Diethylstilbestrol.
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Diethylstilbestrol.
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Diethylstilbestrol.
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Diethylstilbestrol.
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Diethylstilbestrol.
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Diethylstilbestrol.
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Diethylstilbestrol.
FluoxetineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Fluphenazine.
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Diethylstilbestrol.
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Diethylstilbestrol.
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Diethylstilbestrol.
FlurazepamThe serum concentration of Diethylstilbestrol can be increased when it is combined with Flurazepam.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Diethylstilbestrol.
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Diethylstilbestrol.
FluvoxamineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Fluvoxamine.
Fondaparinux sodiumDiethylstilbestrol may decrease the anticoagulant activities of Fondaparinux sodium.
GefitinibThe serum concentration of Diethylstilbestrol can be increased when it is combined with Gefitinib.
GenisteinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Genistein.
GlyburideThe serum concentration of Diethylstilbestrol can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Diethylstilbestrol can be increased when it is combined with Gramicidin D.
GrepafloxacinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Grepafloxacin.
HaloperidolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Haloperidol.
HeparinDiethylstilbestrol may decrease the anticoagulant activities of Heparin.
HirulogDiethylstilbestrol may decrease the anticoagulant activities of Hirulog.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Diethylstilbestrol.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Diethylstilbestrol.
IdelalisibThe serum concentration of Diethylstilbestrol can be increased when it is combined with Idelalisib.
ImatinibThe serum concentration of Diethylstilbestrol can be increased when it is combined with Imatinib.
ImipramineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Imipramine.
IndinavirThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Indinavir.
IndomethacinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Indomethacin.
IsavuconazoniumThe serum concentration of Diethylstilbestrol can be increased when it is combined with Isavuconazonium.
ItraconazoleThe serum concentration of Diethylstilbestrol can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Diethylstilbestrol can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Ivermectin.
KetamineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Ketamine.
KetoconazoleThe serum concentration of Diethylstilbestrol can be increased when it is combined with Ketoconazole.
LansoprazoleThe serum concentration of Diethylstilbestrol can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Diethylstilbestrol can be increased when it is combined with Lapatinib.
LenalidomideDiethylstilbestrol may increase the thrombogenic activities of Lenalidomide.
LepirudinDiethylstilbestrol may decrease the anticoagulant activities of Lepirudin.
LevofloxacinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Levofloxacin.
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Diethylstilbestrol.
LevothyroxineThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Lidocaine.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Diethylstilbestrol.
LiothyronineThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Liothyronine.
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Diethylstilbestrol.
LiotrixThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Diethylstilbestrol can be increased when it is combined with Lisinopril.
LomitapideThe serum concentration of Diethylstilbestrol can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Diethylstilbestrol can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Diethylstilbestrol can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Loratadine.
LosartanThe serum concentration of Diethylstilbestrol can be increased when it is combined with Losartan.
LovastatinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Lovastatin.
LumacaftorThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Lumacaftor.
MaprotilineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Maprotiline.
MebendazoleThe serum concentration of Diethylstilbestrol can be increased when it is combined with Mebendazole.
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Diethylstilbestrol.
MefloquineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Diethylstilbestrol can be increased when it is combined with Megestrol acetate.
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Diethylstilbestrol.
MeprobamateThe serum concentration of Diethylstilbestrol can be increased when it is combined with Meprobamate.
MethadoneThe serum concentration of Diethylstilbestrol can be increased when it is combined with Methadone.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Diethylstilbestrol.
MetoprololThe serum concentration of Diethylstilbestrol can be increased when it is combined with Metoprolol.
MibefradilThe serum concentration of Diethylstilbestrol can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Diethylstilbestrol can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Midazolam.
MifepristoneThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Mifepristone.
MitomycinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Mitomycin.
MitoxantroneThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Mitoxantrone.
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Diethylstilbestrol.
MorphineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Morphine.
NadroparinDiethylstilbestrol may decrease the anticoagulant activities of Nadroparin.
NaltrexoneThe serum concentration of Diethylstilbestrol can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Diethylstilbestrol can be increased when it is combined with Naringenin.
NefazodoneThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Neostigmine.
NicardipineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Nicardipine.
NifedipineThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Nifedipine.
NilotinibThe serum concentration of Diethylstilbestrol can be increased when it is combined with Nilotinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Diethylstilbestrol.
NisoldipineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Diethylstilbestrol can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Nitrendipine.
NorethisteroneThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Norethisterone.
OmeprazoleThe serum concentration of Diethylstilbestrol can be increased when it is combined with Omeprazole.
OspemifeneThe risk or severity of adverse effects can be increased when Diethylstilbestrol is combined with Ospemifene.
OtamixabanDiethylstilbestrol may decrease the anticoagulant activities of Otamixaban.
OuabainOuabain may decrease the cardiotoxic activities of Diethylstilbestrol.
P-NitrophenolThe serum concentration of Diethylstilbestrol can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Diethylstilbestrol can be increased when it is combined with Paclitaxel.
Palmitic AcidThe serum concentration of Diethylstilbestrol can be increased when it is combined with Palmitic Acid.
PantoprazoleThe serum concentration of Diethylstilbestrol can be increased when it is combined with Pantoprazole.
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Diethylstilbestrol.
ParoxetineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Diethylstilbestrol.
Pentosan PolysulfateDiethylstilbestrol may decrease the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe serum concentration of Diethylstilbestrol can be increased when it is combined with Perindopril.
PhenindioneDiethylstilbestrol may decrease the anticoagulant activities of Phenindione.
PhenobarbitalThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Phenobarbital.
PhenprocoumonDiethylstilbestrol may decrease the anticoagulant activities of Phenprocoumon.
PimozideThe serum concentration of Diethylstilbestrol can be increased when it is combined with Pimozide.
Platelet Activating FactorThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Platelet Activating Factor.
PonatinibThe serum concentration of Diethylstilbestrol can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Diethylstilbestrol can be increased when it is combined with Posaconazole.
PravastatinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Pravastatin.
PrazosinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Prazosin.
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Diethylstilbestrol.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Diethylstilbestrol.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Diethylstilbestrol.
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Diethylstilbestrol.
ProbenecidThe serum concentration of Diethylstilbestrol can be increased when it is combined with Probenecid.
ProgesteroneThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Progesterone.
PromethazineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Diethylstilbestrol can be increased when it is combined with Propafenone.
PropranololThe serum concentration of Diethylstilbestrol can be increased when it is combined with Propranolol.
Protein CDiethylstilbestrol may decrease the anticoagulant activities of Protein C.
ProtocatechualdehydeDiethylstilbestrol may decrease the anticoagulant activities of Protocatechualdehyde.
ProtriptylineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Protriptyline.
QuercetinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Quercetin.
QuinacrineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Quinacrine.
QuinidineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Quinine.
RanitidineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Ranolazine.
ReboxetineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Diethylstilbestrol can be increased when it is combined with Regorafenib.
ReserpineThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Reserpine.
ReviparinDiethylstilbestrol may decrease the anticoagulant activities of Reviparin.
RifampicinThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Rifampicin.
RilpivirineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Rilpivirine.
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Diethylstilbestrol.
RitonavirThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Ritonavir.
RivaroxabanDiethylstilbestrol may decrease the anticoagulant activities of Rivaroxaban.
RolapitantThe serum concentration of Diethylstilbestrol can be increased when it is combined with Rolapitant.
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Diethylstilbestrol.
SaquinavirThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Saquinavir.
ScopolamineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Scopolamine.
SelegilineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Selegiline.
SertralineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Sertraline.
SimeprevirThe serum concentration of Diethylstilbestrol can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Sirolimus.
Somatropin recombinantThe therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Diethylstilbestrol.
SorafenibThe serum concentration of Diethylstilbestrol can be increased when it is combined with Sorafenib.
SpironolactoneThe serum concentration of Diethylstilbestrol can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Diethylstilbestrol can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Staurosporine.
StreptozocinThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Streptozocin.
SulfinpyrazoneThe serum concentration of Diethylstilbestrol can be increased when it is combined with Sulfinpyrazone.
SulodexideDiethylstilbestrol may decrease the anticoagulant activities of Sulodexide.
SumatriptanThe serum concentration of Diethylstilbestrol can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Diethylstilbestrol can be increased when it is combined with Sunitinib.
TacrineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Tacrolimus.
TamoxifenThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Tamoxifen.
Taurocholic AcidThe serum concentration of Diethylstilbestrol can be increased when it is combined with Taurocholic Acid.
TelmisartanThe serum concentration of Diethylstilbestrol can be increased when it is combined with Telmisartan.
TemsirolimusThe serum concentration of Diethylstilbestrol can be increased when it is combined with Temsirolimus.
TerazosinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Terazosin.
TerfenadineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Terfenadine.
TesmilifeneThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Diethylstilbestrol can be increased when it is combined with Testosterone.
Testosterone PropionateThe metabolism of Diethylstilbestrol can be decreased when combined with Testosterone Propionate.
ThalidomideDiethylstilbestrol may increase the thrombogenic activities of Thalidomide.
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Diethylstilbestrol.
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Diethylstilbestrol.
TicagrelorThe serum concentration of Diethylstilbestrol can be increased when it is combined with Ticagrelor.
TipranavirDiethylstilbestrol may increase the dermatologic adverse activities of Tipranavir.
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Diethylstilbestrol.
TolcaponeThe metabolism of Diethylstilbestrol can be decreased when combined with Tolcapone.
TolvaptanThe serum concentration of Diethylstilbestrol can be increased when it is combined with Tolvaptan.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Diethylstilbestrol.
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Diethylstilbestrol.
TrazodoneThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Trazodone.
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Diethylstilbestrol.
TrifluoperazineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Triflupromazine.
TrimethoprimThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Trimipramine.
TroleandomycinThe serum concentration of Diethylstilbestrol can be increased when it is combined with Troleandomycin.
Ursodeoxycholic acidThe therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Diethylstilbestrol.
VenlafaxineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Venlafaxine.
VerapamilThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Verapamil.
VinblastineThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Vinorelbine.
Vitamin CThe serum concentration of Diethylstilbestrol can be increased when it is combined with Vitamin C.
WarfarinDiethylstilbestrol may decrease the anticoagulant activities of Warfarin.
XimelagatranDiethylstilbestrol may decrease the anticoagulant activities of Ximelagatran.
ZimelidineThe serum concentration of Diethylstilbestrol can be increased when it is combined with Zimelidine.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription fact...
Gene Name:
ESR1
Uniprot ID:
P03372
Molecular Weight:
66215.45 Da
References
  1. Munoz G, Ovilo C, Estelle J, Silio L, Fernandez A, Rodriguez C: Association with litter size of new polymorphisms on ESR1 and ESR2 genes in a Chinese-European pig line. Genet Sel Evol. 2007 Mar-Apr;39(2):195-206. Epub 2007 Feb 17. [PubMed:17306201 ]
  2. Dixon A, Wells CC, Singh S, Babayan R, Maric C: Renoprotective effects of a selective estrogen receptor modulator, raloxifene, in an animal model of diabetic nephropathy. Am J Nephrol. 2007;27(2):120-8. Epub 2007 Feb 15. [PubMed:17308373 ]
  3. Hart SA, Snyder MA, Smejkalova T, Woolley CS: Estrogen mobilizes a subset of estrogen receptor-alpha-immunoreactive vesicles in inhibitory presynaptic boutons in hippocampal CA1. J Neurosci. 2007 Feb 21;27(8):2102-11. [PubMed:17314305 ]
  4. Baron S, Escande A, Alberola G, Bystricky K, Balaguer P, Richard-Foy H: Estrogen receptor alpha and the activating protein-1 complex cooperate during insulin-like growth factor-I-induced transcriptional activation of the pS2/TFF1 gene. J Biol Chem. 2007 Apr 20;282(16):11732-41. Epub 2007 Feb 22. [PubMed:17317669 ]
  5. Bains M, Cousins JC, Roberts JL: Neuroprotection by estrogen against MPP+-induced dopamine neuron death is mediated by ERalpha in primary cultures of mouse mesencephalon. Exp Neurol. 2007 Apr;204(2):767-76. Epub 2007 Jan 25. [PubMed:17320868 ]
  6. Kwok KC, Cheung NH: Measuring binding kinetics of ligands with tethered receptors by fluorescence polarization and total internal reflection fluorescence. Anal Chem. 2010 May 1;82(9):3819-25. doi: 10.1021/ac1002245. [PubMed:20387803 ]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Orphan receptor that acts as transcription activator in the absence of bound ligand. Binds specifically to an estrogen response element and activates reporter genes controlled by estrogen response elements (By similarity). Induces the expression of PERM1 in the skeletal muscle.
Gene Name:
ESRRG
Uniprot ID:
P62508
Molecular Weight:
51305.485 Da
References
  1. Greschik H, Flaig R, Renaud JP, Moras D: Structural basis for the deactivation of the estrogen-related receptor gamma by diethylstilbestrol or 4-hydroxytamoxifen and determinants of selectivity. J Biol Chem. 2004 Aug 6;279(32):33639-46. Epub 2004 May 24. [PubMed:15161930 ]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Nuclear hormone receptor. Binds estrogens with an affinity similar to that of ESR1, and activates expression of reporter genes containing estrogen response elements (ERE) in an estrogen-dependent manner (PubMed:20074560). Isoform beta-cx lacks ligand binding ability and has no or only very low ere binding activity resulting in the loss of ligand-dependent transactivation ability. DNA-binding by...
Gene Name:
ESR2
Uniprot ID:
Q92731
Molecular Weight:
59215.765 Da
References
  1. Authors unspecified: Final amended report on the safety assessment of Methylparaben, Ethylparaben, Propylparaben, Isopropylparaben, Butylparaben, Isobutylparaben, and Benzylparaben as used in cosmetic products. Int J Toxicol. 2008;27 Suppl 4:1-82. doi: 10.1080/10915810802548359. [PubMed:19101832 ]
  2. Geistlinger TR, McReynolds AC, Guy RK: Ligand-selective inhibition of the interaction of steroid receptor coactivators and estrogen receptor isoforms. Chem Biol. 2004 Feb;11(2):273-81. [PubMed:15123288 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
O-methyltransferase activity
Specific Function:
Catalyzes the O-methylation, and thereby the inactivation, of catecholamine neurotransmitters and catechol hormones. Also shortens the biological half-lives of certain neuroactive drugs, like L-DOPA, alpha-methyl DOPA and isoproterenol.
Gene Name:
COMT
Uniprot ID:
P21964
Molecular Weight:
30036.77 Da
References
  1. Engel LL, Weidenfield J, Merriam GR: Metabolism of diethylstilbestrol by rat liver: a preliminary report. J Toxicol Environ Health Suppl. 1976;1:37-44. [PubMed:11352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxygen binding
Specific Function:
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name:
CYP19A1
Uniprot ID:
P11511
Molecular Weight:
57882.48 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Qu YQ, Fang ZZ, Yang L, Gao ZM, Liang R, Zhu LL, Dong PP, Zhang YY, Ge GB, Wang LM: Reversible inhibition of four important human liver cytochrome P450 enzymes by diethylstilbestrol. Pharmazie. 2011 Mar;66(3):216-21. [PubMed:21553654 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Qu YQ, Fang ZZ, Yang L, Gao ZM, Liang R, Zhu LL, Dong PP, Zhang YY, Ge GB, Wang LM: Reversible inhibition of four important human liver cytochrome P450 enzymes by diethylstilbestrol. Pharmazie. 2011 Mar;66(3):216-21. [PubMed:21553654 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Qu YQ, Fang ZZ, Yang L, Gao ZM, Liang R, Zhu LL, Dong PP, Zhang YY, Ge GB, Wang LM: Reversible inhibition of four important human liver cytochrome P450 enzymes by diethylstilbestrol. Pharmazie. 2011 Mar;66(3):216-21. [PubMed:21553654 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Qu YQ, Fang ZZ, Yang L, Gao ZM, Liang R, Zhu LL, Dong PP, Zhang YY, Ge GB, Wang LM: Reversible inhibition of four important human liver cytochrome P450 enzymes by diethylstilbestrol. Pharmazie. 2011 Mar;66(3):216-21. [PubMed:21553654 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Qu YQ, Fang ZZ, Yang L, Gao ZM, Liang R, Zhu LL, Dong PP, Zhang YY, Ge GB, Wang LM: Reversible inhibition of four important human liver cytochrome P450 enzymes by diethylstilbestrol. Pharmazie. 2011 Mar;66(3):216-21. [PubMed:21553654 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Identical protein binding
Specific Function:
Thyroid hormone-binding protein. Probably transports thyroxine from the bloodstream to the brain.
Gene Name:
TTR
Uniprot ID:
P02766
Molecular Weight:
15886.88 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Sugimoto Y, Tsukahara S, Imai Y, Sugimoto Y, Ueda K, Tsuruo T: Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. Mol Cancer Ther. 2003 Jan;2(1):105-12. [PubMed:12533678 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Rao US, Fine RL, Scarborough GA: Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92. [PubMed:7914405 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23